CClinicalTrials.gg
RecruitingNCT07050212Updated Jul 10, 2025

Application of Remimazolam, Dexmedetomidine, and Esketamine in Pediatric Preoperative Sedation

An interventional study of remimazolam group and dexmedetomidine group in Remimazolam, Dexmedetomidine and Esketamine, sponsored by Maternal and Child Health Hospital of Hubei Province. Recruiting at 1 site in China. Open to participants aged 2 Years to 5 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-07-10.

Sponsored by Maternal and Child Health Hospital of Hubei Province · Not applicable, Interventional, and Prevention

From the registry’s dates

  • Primary completion was expected by Mar 2026, 7 months ago, but the record still lists the study as recruiting.
  • Started Apr 2025; still recruiting 1 year 6 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
2 Years to 5 Years
Sex
All
01

Study summary

By comparing the application effects of three drugs in pediatric preoperative sedation, this study explores the optimal medication regimen, aiming to provide safer, more effective, and more personalized medication options for pediatric preoperative sedation. Additionally, this research will also focus on the impact of these three drugs on postoperative agitation in children, offering valuable references for the overall management of pediatric surgical anesthesia.

Read the detailed description

Participants will be randomly allocated to three groups: remimazolam group(Group A), dexmedetomidine group(Group B), esketamine group(Group C). Before entering the operating room, an intravenous access is established. Under the accompaniment of a parent, one of the three drugs is administered intravenously.

02

Conditions studied

  • Remimazolam
  • Dexmedetomidine
  • Esketamine
03

In context

Lead sponsor

Maternal and Child Health Hospital of Hubei Province is the lead sponsor of 13 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
2 Years to 5 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  1. Children aged 2 to 5 years old
  2. the American Society of Anesthesiologists (ASA) physical status of Class I
  3. scheduled for adenotonsillectomy under general anesthesia, will be included.

Exclusion criteria

Exclusion Criteria:

  1. Abnormal lung function and respiratory system function
  2. airway obstruction or deformity, history of mental illness
  3. electrocardiogram indicating bradycardia
  4. history of cardiac disease
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
150 participants (estimated)

Study arms

  • Experimental
    Remimazolam group: Remimazolam is administered intravenously at a dose of 0.3 mg/kg

    Remimazolam is administered intravenously at a dose of 0.3 mg/kg

    Drug: remimazolam group

  • Active comparator
    dexmedetomidine group: dexmedetomidine is administered intravenously at a dose of 1 μg/kg

    dexmedetomidine is administered intravenously at a dose of 1 μg/kg

    Drug: dexmedetomidine group

  • Active comparator
    esketamine group: esketamine is administered intravenously at a dose of 0.5 mg/kg

    esketamine is administered intravenously at a dose of 0.5 mg/kg

    Drug: esketamine group

Interventions

  • Drugremimazolam group

    remimazolam is administered intravenously at a dose of 0.3 mg/kg

    Also known as: remimazolam

  • Drugdexmedetomidine group

    dexmedetomidine is administered intravenously at a dose of 1 μg/kg

    Also known as: dexmedetomidine

  • Drugesketamine group

    esketamine is administered intravenously at a dose of 0.5 mg/kg

    Also known as: esketamine

06

What researchers measure

Primary outcomes

  1. Sedation success rate

    1 points represents the child being restless and irritable; 2 points represents that the child is quiet and cooperative; 3 points represents that the child is drowsy and able to obey instructions; A score of 4 indicates that the child is in a shallow sleep state and can be quickly awakened; 5 points represent the child falling asleep and having a slow response to calls; 6 points represent the child's deep sleep state and no response to calls. If the Ramasay score greater than 2 points, it is considered a successful sedation.

    Time frame: 0, 3, 5, 10 minutes after the drug injection

  2. Onset time of sedation

    The time from the end of drug injection until the Ramsay score is greater than 2 points. If the Ramasay score greater than 2 points, it is considered a successful sedation. 1 points of ramasay scorere presents the child being restless and irritable; 2 points represents that the child is quiet and cooperative; 3 points represents that the child is drowsy and able to obey instructions; A score of 4 indicates that the child is in a shallow sleep state and can be quickly awakened; 5 points represent the child falling asleep and having a slow response to calls; 6 points represent the child's deep sleep state and no response to calls.

    Time frame: 0, 3, 5, 10 minutes after the drug injection

  3. Parent-Child Separation Anxiety Score (PASA Score)

    if the PASA score is greater than 2, it is considered a positive reaction to separation anxiety. 1 point represents that the child is easily separated from their parents;A score of 2 indicates that the child has crying sounds, easily comforted, and does not rely on their parents;A score of 3 indicates that the child is crying and cannot be comforted, but does not rely on their parents;4 points represent the child crying and relying on their parents

    Time frame: 0, 3, 5, 10 minute after the drug injection

Secondary outcomes

  1. Mask Acceptance Score (MAS)

    The MAS scale is used to evaluate the acceptance of respiratory masks in pediatric patients. Less than 2 points indicate satisfactory acceptance. 1 point represents that the child is fearless and easily accepts face masks; 2 points represent that the child is mildly fear of the face mask and easily be comfort; 3 points represent that the child is moderatly fear of the face mask and cannot be comforted; 4 points represent that the child is very afraid of the face mask and crying

    Time frame: 0, 3, 5, 10 minutes after the drug injection

  2. incidence of adverse reactions

    Time frame: during intravenous bolus administration of sedative drugs and anesthesia induction

  3. restlessness rating scale for awakening period(PAED)

    When the PAED score is greater than 2 points, the child is identified as agitated during the recovery period; if the PAED score is greater than 10 points, the child is identified as delirium in the awakening period.

    Time frame: 0, 5, 10, 20 minutes after the patient awake

  4. Heart rate

    Time frame: 0, 3, 5, and 10 minutes after the drug injection

  5. blood pressure

    systolic pressure and diastolic pressure

    Time frame: 0,3,5,10 minute after drug injectuion

  6. respiratory rate

    Time frame: 0,3,5,10 minute after drug injectuion

  7. pulse oximetry saturation

    Time frame: 0,3,5,10 minute after drug injectuion

07

Study locations

1 of 1 sites recruiting
  • Maternal and Child Health Hospital of Hubei Province
    Wuhan, Hubei 430000, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — I plan to share IPD after the end of this study, including the study protocol, informed consent form and clinical study report.

Supporting information: Study protocol, Icf, Csr

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07050212
Lead sponsor
Maternal and Child Health Hospital of Hubei Province
Responsible party
Li Na (Deputy Chief Physician, Maternal and Child Health Hospital of Hubei Province) — Principal investigator
First posted
Jul 3, 2025
Start date
Apr 1, 2025
Primary completion
Mar 1, 2026 (estimated)
Completion
Mar 1, 2026 (estimated)
Last update
Jul 10, 2025

Study contacts

NaLi, MD
Contact
lina@hbfy.com
+862763490107
Na Li NaLi, MD
principal investigator · Maternal and Child Health Hospital of Hubei Province

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion